Combination of Anti-programmed Cell Death Protein 1 and Antiangiogenesis Displaying a Response Disparity between Pulmonary and Nonpulmonary Metastases
Targeting the vascular endothelial growth factor-mediated immune suppression is a strategy to overcome the resistance of anti-programmed cell death protein 1/programmed death-ligand 1 (anti-PD-1/PD-L1) therapy. Here, we present two cases, including one case with leiomyosarcoma and the other one with...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2023-10-01
|
| Series: | Journal of Cancer Research and Practice |
| Subjects: | |
| Online Access: | https://journals.lww.com/10.4103/ejcrp.eJCRP-D-23-00016 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832591049734750208 |
|---|---|
| author | Bing-Syuan Chung Peng-Chan Lin Shang-Hung Chen Yu-Min Yeh |
| author_facet | Bing-Syuan Chung Peng-Chan Lin Shang-Hung Chen Yu-Min Yeh |
| author_sort | Bing-Syuan Chung |
| collection | DOAJ |
| description | Targeting the vascular endothelial growth factor-mediated immune suppression is a strategy to overcome the resistance of anti-programmed cell death protein 1/programmed death-ligand 1 (anti-PD-1/PD-L1) therapy. Here, we present two cases, including one case with leiomyosarcoma and the other one with microsatellite-stable colorectal cancer, receiving the combination of pembrolizumab and lenvatinib as salvage treatment. Both cases demonstrated a significant response in lung metastases; however, the nonpulmonary metastases progressed. These findings suggest that lung metastasis might have a distinct tumor immune microenvironment, and further studies to investigate the efficacy of PD-1/PD-L1-based combination therapy in patients with lung-limited metastases are warranted. |
| format | Article |
| id | doaj-art-a583c61db885465fb2853bbc485c68c4 |
| institution | Kabale University |
| issn | 2311-3006 |
| language | English |
| publishDate | 2023-10-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Journal of Cancer Research and Practice |
| spelling | doaj-art-a583c61db885465fb2853bbc485c68c42025-01-23T05:09:09ZengWolters Kluwer Medknow PublicationsJournal of Cancer Research and Practice2311-30062023-10-0110415015310.4103/ejcrp.eJCRP-D-23-00016Combination of Anti-programmed Cell Death Protein 1 and Antiangiogenesis Displaying a Response Disparity between Pulmonary and Nonpulmonary MetastasesBing-Syuan ChungPeng-Chan LinShang-Hung ChenYu-Min YehTargeting the vascular endothelial growth factor-mediated immune suppression is a strategy to overcome the resistance of anti-programmed cell death protein 1/programmed death-ligand 1 (anti-PD-1/PD-L1) therapy. Here, we present two cases, including one case with leiomyosarcoma and the other one with microsatellite-stable colorectal cancer, receiving the combination of pembrolizumab and lenvatinib as salvage treatment. Both cases demonstrated a significant response in lung metastases; however, the nonpulmonary metastases progressed. These findings suggest that lung metastasis might have a distinct tumor immune microenvironment, and further studies to investigate the efficacy of PD-1/PD-L1-based combination therapy in patients with lung-limited metastases are warranted.https://journals.lww.com/10.4103/ejcrp.eJCRP-D-23-00016colorectal cancerimmunotherapyleiomyosarcomatumor microenvironmentvascular endothelial growth factor-targeted therapy |
| spellingShingle | Bing-Syuan Chung Peng-Chan Lin Shang-Hung Chen Yu-Min Yeh Combination of Anti-programmed Cell Death Protein 1 and Antiangiogenesis Displaying a Response Disparity between Pulmonary and Nonpulmonary Metastases Journal of Cancer Research and Practice colorectal cancer immunotherapy leiomyosarcoma tumor microenvironment vascular endothelial growth factor-targeted therapy |
| title | Combination of Anti-programmed Cell Death Protein 1 and Antiangiogenesis Displaying a Response Disparity between Pulmonary and Nonpulmonary Metastases |
| title_full | Combination of Anti-programmed Cell Death Protein 1 and Antiangiogenesis Displaying a Response Disparity between Pulmonary and Nonpulmonary Metastases |
| title_fullStr | Combination of Anti-programmed Cell Death Protein 1 and Antiangiogenesis Displaying a Response Disparity between Pulmonary and Nonpulmonary Metastases |
| title_full_unstemmed | Combination of Anti-programmed Cell Death Protein 1 and Antiangiogenesis Displaying a Response Disparity between Pulmonary and Nonpulmonary Metastases |
| title_short | Combination of Anti-programmed Cell Death Protein 1 and Antiangiogenesis Displaying a Response Disparity between Pulmonary and Nonpulmonary Metastases |
| title_sort | combination of anti programmed cell death protein 1 and antiangiogenesis displaying a response disparity between pulmonary and nonpulmonary metastases |
| topic | colorectal cancer immunotherapy leiomyosarcoma tumor microenvironment vascular endothelial growth factor-targeted therapy |
| url | https://journals.lww.com/10.4103/ejcrp.eJCRP-D-23-00016 |
| work_keys_str_mv | AT bingsyuanchung combinationofantiprogrammedcelldeathprotein1andantiangiogenesisdisplayingaresponsedisparitybetweenpulmonaryandnonpulmonarymetastases AT pengchanlin combinationofantiprogrammedcelldeathprotein1andantiangiogenesisdisplayingaresponsedisparitybetweenpulmonaryandnonpulmonarymetastases AT shanghungchen combinationofantiprogrammedcelldeathprotein1andantiangiogenesisdisplayingaresponsedisparitybetweenpulmonaryandnonpulmonarymetastases AT yuminyeh combinationofantiprogrammedcelldeathprotein1andantiangiogenesisdisplayingaresponsedisparitybetweenpulmonaryandnonpulmonarymetastases |